✦ LIBER ✦
9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405
✍ Scribed by Tsurutani, J.; Mitsudomi, T.; Mori, S.; Okamoto, I.; Kaname, N.; Tada, H.; Negoro, S.; Yatabe, Y.; Fukuoka, M.; Nakagawa, K.
- Book ID
- 123311080
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 49 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.